Firmen mit starken bis bombenstarken Margen - 500 Beiträge pro Seite
eröffnet am 29.12.14 23:33:33 von
neuester Beitrag 26.07.18 17:27:08 von
neuester Beitrag 26.07.18 17:27:08 von
Beiträge: 86
ID: 1.204.964
ID: 1.204.964
Aufrufe heute: 0
Gesamt: 7.821
Gesamt: 7.821
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
vor 1 Stunde | 2399 | |
vor 52 Minuten | 1955 | |
vor 1 Stunde | 1827 | |
08.05.24, 11:56 | 1818 | |
vor 52 Minuten | 1333 | |
vor 55 Minuten | 1282 | |
vor 1 Stunde | 1085 | |
gestern 17:20 | 853 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.772,85 | +0,46 | 131 | |||
2. | 3. | 0,2170 | +3,33 | 125 | |||
3. | Neu! | 8,2570 | +96,67 | 108 | |||
4. | 4. | 156,46 | -2,31 | 103 | |||
5. | 14. | 5,7540 | -2,18 | 56 | |||
6. | 2. | 0,2980 | -3,87 | 50 | |||
7. | 5. | 2,3720 | -7,54 | 49 | |||
8. | 7. | 6,8000 | +2,38 | 38 |
können hier eingestellt werden
die können diese Margen, schon, haben, oder Spekulation darauf sein dass die(se) später eintreten werden
für mich ist Marge eines DER Kriterien, allerdings auch als -"nur"- Spekulation, später, darauf
stark/bombenstark habe ich im Archiv aufm PC so definiert stark: miiindestens 15% (Netto)Marge, lieber 20% aufwärts, "bombenstark" 30% Nettomarge aufwärts
da wird die Luft dann schon eng, aber es gibt hin und wieder solche Firmen(vor aaallem -anteilsmässig- in "Emerging Markets"/(noch)nicht so stark regulierten Ländern würde ich sagen)
der Thread beabsichtigt nicht Kauf/Verkaufempfehlungen zu geben, sondern, quasi, nur Rechercheanreize
zu Firmen unter einem bestimmten Gesichtspunkt
ich habe 0 Erwartungen dazu-solche Dinge(r) müssen, auch, selbstständig laufen-, aber wenn Einwürfe und Vorschläge dazu kommen wäre das interessant
die 1. Firma zum Thema -Abcam Plc
www.edisoninvestmentresearch.com/serve_pdf.php?d=monthlybook…
http://financials.morningstar.com/ratios/r.html?t=ABC®ion…
die können diese Margen, schon, haben, oder Spekulation darauf sein dass die(se) später eintreten werden
für mich ist Marge eines DER Kriterien, allerdings auch als -"nur"- Spekulation, später, darauf
stark/bombenstark habe ich im Archiv aufm PC so definiert stark: miiindestens 15% (Netto)Marge, lieber 20% aufwärts, "bombenstark" 30% Nettomarge aufwärts
da wird die Luft dann schon eng, aber es gibt hin und wieder solche Firmen(vor aaallem -anteilsmässig- in "Emerging Markets"/(noch)nicht so stark regulierten Ländern würde ich sagen)
der Thread beabsichtigt nicht Kauf/Verkaufempfehlungen zu geben, sondern, quasi, nur Rechercheanreize
zu Firmen unter einem bestimmten Gesichtspunkt
ich habe 0 Erwartungen dazu-solche Dinge(r) müssen, auch, selbstständig laufen-, aber wenn Einwürfe und Vorschläge dazu kommen wäre das interessant
die 1. Firma zum Thema -Abcam Plc
www.edisoninvestmentresearch.com/serve_pdf.php?d=monthlybook…
http://financials.morningstar.com/ratios/r.html?t=ABC®ion…
Wäre noch schön zu erwähnen, was die machen, ohne auf die Seite gehen zu müssen...
Antwort auf Beitrag Nr.: 48.663.614 von Popeye82 am 29.12.14 23:33:33bombenstarken Margen
immer diese lästige Kriegsrethorik
immer diese lästige Kriegsrethorik
Antwort auf Beitrag Nr.: 48.666.350 von dummilein am 30.12.14 12:47:35
da wären auch andere Termina zu benutzen gewesen
es sollte nur ausdrücken dass es noch eine Steigerung zu "stark" ist
da uns solche Margen, inn unseren Breitengraden, denke ich ja nicht gerade "normal" sind
Gruß
P.
da wären auch andere Termina zu benutzen gewesen
es sollte nur ausdrücken dass es noch eine Steigerung zu "stark" ist
da uns solche Margen, inn unseren Breitengraden, denke ich ja nicht gerade "normal" sind
Gruß
P.
Antwort auf Beitrag Nr.: 48.663.635 von ElfenbeinelaufenschnellermitKo am 29.12.14 23:37:10
Antwort auf Beitrag Nr.: 48.666.350 von dummilein am 30.12.14 12:47:35
Zitat von dummilein: bombenstarken Margen
immer diese lästige Kriegsrethorik
http://investor.fleetcor.com/phoenix.zhtml?c=236217&p=irol-i…
http://financials.morningstar.com/ratios/r.html?t=FLT®ion…
stehen bei mir ganz oben auf der kaufliste 2015
http://financials.morningstar.com/ratios/r.html?t=FLT®ion…
stehen bei mir ganz oben auf der kaufliste 2015
Antwort auf Beitrag Nr.: 48.669.230 von harenberg77 am 30.12.14 18:26:57
die sehen doch -in diesem Zusammenhang, jedenfalls- doch erstmal gut aus
so müsste der Link funktionieren
sehen jetzt fürs Erste auch nicht massiv teuer aus
http://financials.morningstar.com/ratios/r.html?t=FLT®ion…
Gruß
P.
die sehen doch -in diesem Zusammenhang, jedenfalls- doch erstmal gut aus
so müsste der Link funktionieren
sehen jetzt fürs Erste auch nicht massiv teuer aus
http://financials.morningstar.com/ratios/r.html?t=FLT®ion…
Gruß
P.
Antwort auf Beitrag Nr.: 48.663.614 von Popeye82 am 29.12.14 23:33:33
ich möchte das Threadthema gern noch ein bisschen erweitern, es sinngemäss aber belassen
eine Rohstofffirma, gewissermassen ein "Kandidat"
Highfield Resources - Completes Compelling DFS, 'Confirms 'High Margin, Low Capex Potential', for Muga Mine' - Mar 30, 2015
+ Definitive Feasibility Study(DFS) completed delivering:
- Post tax unlevered project NPV10 of US$1,420,000,000
- Post tax, unlevered IRR of 51.9%
- EBITDA in 1st full year of production of US$296,000,000(EBITDA margin of 66%)
+ Ore Reserve of 146,000,000 tonnes @average grade of 12.73% K20
+ Initial 24 year mine life, based solely on reserves
+ Proposed mine is a technically robust underground conventional room pillar operation, via twin decline access, which enhances operational efficiency +reduces risk
+ Average yearly, steady state production of 1,123,000 tonnes of granular K60 potash, with operational expenditure(“opex”) in full production estimated @US$135/tonne
+ Independent expert spot potash prices discounted by 10%, for contract pricing +sales +marketing fees, delivering a '17 FOB Vancouver standard product reference price of US$315 / tonne in real terms
+ Pre-production capital cost estimated @US$256,000,000, including a 12.5% contingency
+ Total capital cost estimated @US$354,000,000 including 12.5% contingency
+ DFS peer reviewed by Canadian based international engineering firm, for gap analysis on both capex +opex
+ Construction tenders to be released to Spanish contractors next quarter
+ Construction remains on track for Q4 '15 ...
www.vision6.com.au/download/files/41167/1916610/HFR-ASX%20%2…
http://stocknessmonster.com/news-item?S=HFR&E=ASX&N=714416
www.highfieldresources.com.au/wp-content/uploads/sites/2/201…
Zitat von Popeye82: Firmen mit starken bis bombenstarken Margen
ich möchte das Threadthema gern noch ein bisschen erweitern, es sinngemäss aber belassen
eine Rohstofffirma, gewissermassen ein "Kandidat"
Highfield Resources - Completes Compelling DFS, 'Confirms 'High Margin, Low Capex Potential', for Muga Mine' - Mar 30, 2015
+ Definitive Feasibility Study(DFS) completed delivering:
- Post tax unlevered project NPV10 of US$1,420,000,000
- Post tax, unlevered IRR of 51.9%
- EBITDA in 1st full year of production of US$296,000,000(EBITDA margin of 66%)
+ Ore Reserve of 146,000,000 tonnes @average grade of 12.73% K20
+ Initial 24 year mine life, based solely on reserves
+ Proposed mine is a technically robust underground conventional room pillar operation, via twin decline access, which enhances operational efficiency +reduces risk
+ Average yearly, steady state production of 1,123,000 tonnes of granular K60 potash, with operational expenditure(“opex”) in full production estimated @US$135/tonne
+ Independent expert spot potash prices discounted by 10%, for contract pricing +sales +marketing fees, delivering a '17 FOB Vancouver standard product reference price of US$315 / tonne in real terms
+ Pre-production capital cost estimated @US$256,000,000, including a 12.5% contingency
+ Total capital cost estimated @US$354,000,000 including 12.5% contingency
+ DFS peer reviewed by Canadian based international engineering firm, for gap analysis on both capex +opex
+ Construction tenders to be released to Spanish contractors next quarter
+ Construction remains on track for Q4 '15 ...
www.vision6.com.au/download/files/41167/1916610/HFR-ASX%20%2…
http://stocknessmonster.com/news-item?S=HFR&E=ASX&N=714416
www.highfieldresources.com.au/wp-content/uploads/sites/2/201…
ein weiterer "Kandidat" -Arch Therapeutics
ich finde diese Firma hoch interessant, habe sie aber, bis dato, nicht
Arch Therapeutics - SeeThruEquity Initiates Research Coverage - Nov 5, 2014
- Ajay Tandon, Brandon Primack, CFA -
- "HLs"
- AC5TM is a "transformative product" for the surgical sealant market. Arch is currently developing the 'AC5 Surgical Hemostatic Device™', as an approach to the 'rapid cessation of bleeding'(hemostasis) +'control of fluid leakage'(sealant), during surgery +trauma care. AC5™ is designed to achieve hemostasis in minimally invasive(laparoscopic) +open surgical procedures. Developed by Arch Co-Founder Dr. Rutledge Ellis-Behnke, PhD, +licensed from the Massachusetts Institute of Technology, AC5™ is a synthetic peptide comprising naturally occurring amino acids. When AC5™ is applied directly onto a surgical or traumatic wound, it 'rapidly creates a physical barrier in the nooks +crannies of the tissue, +prooooomptly stops bleeding +fluid leaks'.
- AC5™ will be a 'highly differentiated competitor' in large, unsatisfied market. Arch spoke with surgeons, operating room managers, sales representatives for competitive products, +'hospital administrative decision-makers' regarding their thoughts on what they wanted in an 'ideal product' +incorporated these features into the design of AC5™. It is estimated that during both open +laparoscopic surgery, 30-50% of procedure time can be spent controlling bleeding, +currently available biomaterials are associated with a range of drawbacks, which AC5 'appears to avoid'.
- 'Significant market opportunity'. Arch "believes" that AC5™ "will" have initial applications in both, the hemostatic +sealant markets, which were "estimated" to be $4,500,000,000 globally in '13. These are 'very attractive end markets', which are "expected" to grow @~10%/year, through '17E, totaling $6,700,000,000. Within this market, sales of fibrin sealants were ~$1,300,000,000.
- 'Compelling' early results. AC5™ has not yet been tested in human trials, but in preclinical animal testing, the results have been "quite dramatic". AC5™ has been tested in brain, liver +spinal cord tissue, +has shown very consistent results. With AC5™, the time to hemostasis is typically measured in seeeconds, compared to miiiiinutes for 'most of the product's competition'. To date, biocompatibility has been 'excellent', +healing of tissue treated with the device has been normal. Arch has started biocompatibility studies +plans to initiate a non-US clinical trial in 4Q14. On Aug 25,'14, Arch reported positive data in an initial preclinical study, assessing the use of its 'AC5 Surgical Hemostatic Device™' in animals, receiving an anticoagulant medication(i.e. blood thinner). ...-
ajay@seethruequity.com
(646) 495-0939
brandon@seethruequity.com
(646) 495-0939
http://media.wix.com/ugd/a15970_f5c26d1e86e84315987d298a05b9…
http://content.stockpr.com/archtherapeutics/media/c2b2fbc52b…
http://edge.media-server.com/m/p/yegp8cik
ich finde diese Firma hoch interessant, habe sie aber, bis dato, nicht
Arch Therapeutics - SeeThruEquity Initiates Research Coverage - Nov 5, 2014
- Ajay Tandon, Brandon Primack, CFA -
- "HLs"
- AC5TM is a "transformative product" for the surgical sealant market. Arch is currently developing the 'AC5 Surgical Hemostatic Device™', as an approach to the 'rapid cessation of bleeding'(hemostasis) +'control of fluid leakage'(sealant), during surgery +trauma care. AC5™ is designed to achieve hemostasis in minimally invasive(laparoscopic) +open surgical procedures. Developed by Arch Co-Founder Dr. Rutledge Ellis-Behnke, PhD, +licensed from the Massachusetts Institute of Technology, AC5™ is a synthetic peptide comprising naturally occurring amino acids. When AC5™ is applied directly onto a surgical or traumatic wound, it 'rapidly creates a physical barrier in the nooks +crannies of the tissue, +prooooomptly stops bleeding +fluid leaks'.
- AC5™ will be a 'highly differentiated competitor' in large, unsatisfied market. Arch spoke with surgeons, operating room managers, sales representatives for competitive products, +'hospital administrative decision-makers' regarding their thoughts on what they wanted in an 'ideal product' +incorporated these features into the design of AC5™. It is estimated that during both open +laparoscopic surgery, 30-50% of procedure time can be spent controlling bleeding, +currently available biomaterials are associated with a range of drawbacks, which AC5 'appears to avoid'.
- 'Significant market opportunity'. Arch "believes" that AC5™ "will" have initial applications in both, the hemostatic +sealant markets, which were "estimated" to be $4,500,000,000 globally in '13. These are 'very attractive end markets', which are "expected" to grow @~10%/year, through '17E, totaling $6,700,000,000. Within this market, sales of fibrin sealants were ~$1,300,000,000.
- 'Compelling' early results. AC5™ has not yet been tested in human trials, but in preclinical animal testing, the results have been "quite dramatic". AC5™ has been tested in brain, liver +spinal cord tissue, +has shown very consistent results. With AC5™, the time to hemostasis is typically measured in seeeconds, compared to miiiiinutes for 'most of the product's competition'. To date, biocompatibility has been 'excellent', +healing of tissue treated with the device has been normal. Arch has started biocompatibility studies +plans to initiate a non-US clinical trial in 4Q14. On Aug 25,'14, Arch reported positive data in an initial preclinical study, assessing the use of its 'AC5 Surgical Hemostatic Device™' in animals, receiving an anticoagulant medication(i.e. blood thinner). ...-
ajay@seethruequity.com
(646) 495-0939
brandon@seethruequity.com
(646) 495-0939
http://media.wix.com/ugd/a15970_f5c26d1e86e84315987d298a05b9…
http://content.stockpr.com/archtherapeutics/media/c2b2fbc52b…
http://edge.media-server.com/m/p/yegp8cik
Vielleicht stehe ich ja auf dem Schlauch, aber wo sind die "bombenstarken Margen"?
Antwort auf Beitrag Nr.: 49.568.387 von sdaktien am 15.04.15 12:50:05
welche der Beiden meinst Du?
welche der Beiden meinst Du?
Arch Therapeutics.
Antwort auf Beitrag Nr.: 49.573.694 von sdaktien am 15.04.15 22:13:40
im ersten Post hatte ich ja geschrieben
"die können diese Margen, schon, haben, oder Spekulation darauf sein dass die(se) später eintreten werden"
und zu Arch dann "Kandidat" geschrieben
zu dem gemeinten mit "erweitern", da hatte ich auch noch ein bisschen mehr in diese Richtung im SInn
wenn Du bei Arch Recherche/Presentation/Cast anschaust wirst Du sehen dass der CEO öfter von "potential high margin biz" spricht
was das genauer heisst habe ich -schon ein bisschen versucht, aber- bis jetzt noch nicht rausgefunden
im ersten Post hatte ich ja geschrieben
"die können diese Margen, schon, haben, oder Spekulation darauf sein dass die(se) später eintreten werden"
und zu Arch dann "Kandidat" geschrieben
zu dem gemeinten mit "erweitern", da hatte ich auch noch ein bisschen mehr in diese Richtung im SInn
wenn Du bei Arch Recherche/Presentation/Cast anschaust wirst Du sehen dass der CEO öfter von "potential high margin biz" spricht
was das genauer heisst habe ich -schon ein bisschen versucht, aber- bis jetzt noch nicht rausgefunden
Danke
Ich hatte nur den letzten Post gelesen. Normalerweise bist du immer kurz und präzise. Im Gegensatz zu mir *grins*
Ich hatte nur den letzten Post gelesen. Normalerweise bist du immer kurz und präzise. Im Gegensatz zu mir *grins*
Antwort auf Beitrag Nr.: 49.583.036 von sdaktien am 16.04.15 20:44:26
kein Ding
Du kannst auch gern lang sein
aber, das ist einfach so eine Grundsatzsache -ich hab keine, sag ich jetzt nicht, Lust auf so verblödete Sinnlosdiskussionen
wenn jemand ernsthaft diskutieren will geb ich mir normalerweise Mühe, (aber)in anderen Fällen kann das auch, recht arg, ins Gegenteil ausschlagen
kein Ding
Du kannst auch gern lang sein
aber, das ist einfach so eine Grundsatzsache -ich hab keine, sag ich jetzt nicht, Lust auf so verblödete Sinnlosdiskussionen
wenn jemand ernsthaft diskutieren will geb ich mir normalerweise Mühe, (aber)in anderen Fällen kann das auch, recht arg, ins Gegenteil ausschlagen
ein weiterer "Kandidat"
ich bin in diese Firma mal spekulativ eingestiegen
das Video ist schon (gut)1 Jahr alt
http://noble.mediasite.com/mediasite/Play/da58d46f464b48dca8…
habe noch einige weitere, die dann immer mal so step by step
von den hier genannten Abcam hab ich nicht, Highfield hab ich, Arch nicht, Vaccinogen ja
ich bin in diese Firma mal spekulativ eingestiegen
das Video ist schon (gut)1 Jahr alt
http://noble.mediasite.com/mediasite/Play/da58d46f464b48dca8…
habe noch einige weitere, die dann immer mal so step by step
von den hier genannten Abcam hab ich nicht, Highfield hab ich, Arch nicht, Vaccinogen ja
vielleicht etwas
die Angaben zu Umsatz/Earnings sind, soweit, finde ich jedenfalls ziemlicher Knaller
übersetzt über 40% net marge
"Seeking a way to invest in the rising affluence and health consciousness of the middle classes in China?
This company is well worth reviewing.
Dongfang is a Ganzhou based plantation company harvesting tangerines, grapefruit and oranges in a >A$170m revenue business that generates around A$70m in earnings. The company has no debt.
Growth in revenues and earnings has been strong through the clear focus on these basic products and all earnings have been reinvested in the business.
It is an aggregator of local co-operatives and is able to make good progress in what are very obviously highly fragmented industries.
It will use the new capital and cashflows to acquire additional plantations (orchards) to maintain the growth.
China has a taxation exemption for food agricultural businesses and gives great policy encouragement to the sector.
Even the new plantations are considered part of China’s reafforestation planning.
The company is also seeking to expand its camellia nut oil ( similar and almost equivalent to olive oil) production and establish one of China’s first larger scale oil production facilities in what is also a highly fragmented industry.
There is very strong interest from admiring large Chinese investors who are waiting to join Dongfang in the equity market boom (Shanghai is up >100% in the past year) without enduring the 3-5 year wait currently applying to new listings on Shanghai or Shenzhen.
I am presenting on a proposed IPO of the remarkable and very profitable citrus fruit producer Donfang Modern Agricultural company
7 February
Barry Dawes is presenting at the Symposium:
Melbourne - Tuesday 21st April - Lunch
Sydney - Wednesday 22nd April - 5pm
We will be talking Dongfang Modern Agricultural company, the proposed IPO, and the Chinese market.
Please be sure to book your tickets with the Investor Roeadshow
The IPO will be priced at about 5.0xPER and it will have about 20% payout in the first years.
Applications can only be made via the Prospectus which has not yet been lodged.
I will be seeking investors, particularly for spread, on this IPO.
Please confirm your availability as soon as possible..To register for Melbourne this Tuesday 21st April at lunchtime or Sydney this Wednesday from 5pm please click here http://symposium.net.au/InvestorRoadshow "
die Angaben zu Umsatz/Earnings sind, soweit, finde ich jedenfalls ziemlicher Knaller
übersetzt über 40% net marge
"Seeking a way to invest in the rising affluence and health consciousness of the middle classes in China?
This company is well worth reviewing.
Dongfang is a Ganzhou based plantation company harvesting tangerines, grapefruit and oranges in a >A$170m revenue business that generates around A$70m in earnings. The company has no debt.
Growth in revenues and earnings has been strong through the clear focus on these basic products and all earnings have been reinvested in the business.
It is an aggregator of local co-operatives and is able to make good progress in what are very obviously highly fragmented industries.
It will use the new capital and cashflows to acquire additional plantations (orchards) to maintain the growth.
China has a taxation exemption for food agricultural businesses and gives great policy encouragement to the sector.
Even the new plantations are considered part of China’s reafforestation planning.
The company is also seeking to expand its camellia nut oil ( similar and almost equivalent to olive oil) production and establish one of China’s first larger scale oil production facilities in what is also a highly fragmented industry.
There is very strong interest from admiring large Chinese investors who are waiting to join Dongfang in the equity market boom (Shanghai is up >100% in the past year) without enduring the 3-5 year wait currently applying to new listings on Shanghai or Shenzhen.
I am presenting on a proposed IPO of the remarkable and very profitable citrus fruit producer Donfang Modern Agricultural company
7 February
Barry Dawes is presenting at the Symposium:
Melbourne - Tuesday 21st April - Lunch
Sydney - Wednesday 22nd April - 5pm
We will be talking Dongfang Modern Agricultural company, the proposed IPO, and the Chinese market.
Please be sure to book your tickets with the Investor Roeadshow
The IPO will be priced at about 5.0xPER and it will have about 20% payout in the first years.
Applications can only be made via the Prospectus which has not yet been lodged.
I will be seeking investors, particularly for spread, on this IPO.
Please confirm your availability as soon as possible..To register for Melbourne this Tuesday 21st April at lunchtime or Sydney this Wednesday from 5pm please click here http://symposium.net.au/InvestorRoadshow "
eine Firma mit soweit ich das sehe hoher Marge -ARM Holdings PLC
mit einem, für diese Firmen wohl nicht ungewöhnlichem -wenn nicht geraaade einem der "Merkmale"- -abartig hohem - hohem KUV
kleine Dividende gibt es, und sind über die letzten jahre anständig gewachsen, in wie es aussieht "so ziemlich allen Kennziffern"
scheinen irgendwas richtig gemacht zu haben
ichh vermute stark die stecken den Großteil Ihres Geldes in IR
www.arm.com/about/newsroom/arm-holdings-plc-reports-results-…
http://financials.morningstar.com/ratios/r.html?t=ARMH®io…
http://media.corporate-ir.net/media_files/IROL/19/197211/Inv…
mit einem, für diese Firmen wohl nicht ungewöhnlichem -wenn nicht geraaade einem der "Merkmale"- -abartig hohem - hohem KUV
kleine Dividende gibt es, und sind über die letzten jahre anständig gewachsen, in wie es aussieht "so ziemlich allen Kennziffern"
scheinen irgendwas richtig gemacht zu haben
ichh vermute stark die stecken den Großteil Ihres Geldes in IR
www.arm.com/about/newsroom/arm-holdings-plc-reports-results-…
http://financials.morningstar.com/ratios/r.html?t=ARMH®io…
http://media.corporate-ir.net/media_files/IROL/19/197211/Inv…
ein weiterer Kandidat
die habe ich auch
für den Grundmechanismus des CTL Verfahrens, und eine kurze deutsche Zusammenfassung, am Besten mal folgenden Link anschauen, @Beitrag Nr. 1.734
www.wallstreet-online.de/diskussion/1162378-1731-1740/argex-…
Argex reports on '14 &provides operational outlook, for upcoming 1st Plant - Apr 9, 2015
+ PROCESS SCRUTINIZED AND AWARDED WITH INTERNATIONAL RECOGNITION
+ TARGETED REVENUES OF US$145 MILLION TO US$155 MILLION &TARGETED EBITDA MARGINS OF 45% TO 52%, FROM FIRST COMMERCIAL PRODUCTION PLANT
http://argex.ca/images/pdf/en/News-Releases/2015/Argex_Titan…
www.argex.ca/images/pdf/en/Presentation/Argex_IR_Presentatio…
"MONTREAL, April 9, 2015 /CNW Telbec/ - Argex Titanium, Inc. (RGX.TO), an emerging producer of high-grade titanium dioxide (TiO2) used as white pigment in paint, plastic, paper, cosmetics and other applications, announced that it has filed its financial results for the year ended December 31, 2014 on www.sedar.com and provided updated estimates related to the construction and operation of its first commercially sized TiO2 production facility to be located in Salaberry-de-Valleyfield, Quebec (the "Plant").
"During 2014, we achieved significant milestones including securing an exclusive long-term marketing and supply agreement with Helm U.S. Corp.," stated Roy Bonnell, President and CEO. "We raised CAD $7.5 million through the issuance of convertible debentures and exited 2014 with a clean capital structure as all remaining warrants have been exercised or expired."
"Furthermore, in December of 2014 Argex received an ICIS Innovation Award. The annual ICIS Innovation Awards recognizes chemical companies that demonstrate an innovative approach to business, the environment and/or sustainability. We are proud to be counted among the very best innovators," he added.
In February 2015, Argex announced that it had successfully completed technical due diligence associated with the financing of Argex's first Plant.
"We are pleased to have passed this major financing milestone," stated Roy Bonnell. "The technical diligence was demanding and thorough and contributed positively to the development of our financing process and our strategy of risk mitigation. Argex is poised for the next phase of its growth – the successful construction and operation of its first Plant."
Plant Operating Model
Argex has updated its target Plant operating model (the "Model") based on prevailing North American TiO2 prices and information gathered in connection with the technical due diligence process conducted by its potential financial sponsors, from marketing partners, internal estimates, equipment providers, and other third parties.
The following is a summary of Argex's Model based on the assumption of scale-up to full capacity. Argex currently estimates that full capacity of the Plant will be achieved approximately 12 months after commencement of commercial operations.
Argex's Plant Target Operating Model (in US Dollars):
- Worldwide TiO2 Market – 5.7 million tonnes / year
- Plant Capacity – 50,000 tonnes / year
- Revenue – $145 million to $155 million
- Gross Profit – $80 million to $96 million
- Gross Margin – 55% to 62%
- EBITDA – $65 million - $81 million
- EBITDA Margin – 45% to 52%
The Model referenced above is based on a number of assumptions and variables, such as product and by-product selling prices, product quality, ore selection, production yields, input costs, shipping costs, feedstock and chemicals costs, overhead costs, product mix, staffing estimates, foreign exchange rates and other inputs, all of which may be subject to change.
For information regarding the non-IFRS financial measures discussed in this release, please see "Non-IFRS Financial Measures" below.
Construction of Plant in Valleyfield Port Area
In its 2015 budget, the Quebec Government announced its plans to allocate CAD $1.5 billion to support its maritime strategy, including CAD $450 million to attract private investment by focusing on logistical and port infrastructure.
Argex has now secured a one million square foot parcel of land where it plans to build a customized building rather than to renovate and modify the existing building where Argex's pilot plant will continue to be situated. The parcel of land to be purchased from and rezoned by the City of Valleyfield, is located in the Valleyfield Port area and is expected to result in the following advantages as compared to the previously proposed site:
- Equivalent capital cost (including contingency risks), reduced construction risk as the potential for unknown liabilities and requirements to tear down, move or expand buildings and fixtures, are avoided.
- Increased building height and equipment layout flexibility.
- Closer proximity, with a rail spur easement, to a local CSX rail terminal and to the Port of Valleyfield.
- Closer proximity to a major chemical feedstock provider.
- Reduced operating expense.
- No change in construction timeline.
Non-IFRS financial measures
To supplement Argex's financial information presented in accordance with international financial reporting standards, or IFRS, Argex considers certain financial measures in evaluating its operating results and for financial and operational decision-making purposes. Financial measures not standardized under IFRS used by the Corporation, in this regard, such as earnings before interest, income taxes, depreciation and amortization (EBITDA), are not calculated in accordance with or recognized by IFRS. EBITDA should not be considered as an alternative to net income in measuring Argex's performance, nor should it be used as a measure of cash flow. EBITDA as calculated by Argex is equivalent to operating revenues less total operating, selling, general and administrative, and research and development costs. The Corporation's method of calculating these non-IFRS financial measures may differ from the methods used by other companies and, as a result, the non-IFRS financial measures presented in this document may not be comparable to other similarly titled measures disclosed by other companies. Argex's target Plant operating Model references EBITDA, a non-IFRS measure. EBITDA is calculated as net earnings before interest, depreciation, amortization and taxes, the "Reconciling Items". The Company is currently unable to provide a reconciliation to net income or loss as the amounts of the reconciling items, and in particular interest costs, associated with the Plant, are currently inestimable.
About Argex Titanium
Argex Titanium Inc. has developed an advanced chemical process for the volume production of high grade titanium dioxide (TiO2) for use in high quality paint, plastics, cosmetics and other applications. The Company's unique proprietary process takes relatively inexpensive and plentiful source material from a variety of potential vendors, and produces TiO2 along with other valuable by-products. Argex's process provides a significant cost and environmental advantage over current legacy TiO2 production methods. The Company's primary near term goal is to rapidly advance toward a 50,000 tonne per annum production module as a first step in its goal to transform the 5.7 million tonne per annum TiO2 industry. "
die habe ich auch
für den Grundmechanismus des CTL Verfahrens, und eine kurze deutsche Zusammenfassung, am Besten mal folgenden Link anschauen, @Beitrag Nr. 1.734
www.wallstreet-online.de/diskussion/1162378-1731-1740/argex-…
Argex reports on '14 &provides operational outlook, for upcoming 1st Plant - Apr 9, 2015
+ PROCESS SCRUTINIZED AND AWARDED WITH INTERNATIONAL RECOGNITION
+ TARGETED REVENUES OF US$145 MILLION TO US$155 MILLION &TARGETED EBITDA MARGINS OF 45% TO 52%, FROM FIRST COMMERCIAL PRODUCTION PLANT
http://argex.ca/images/pdf/en/News-Releases/2015/Argex_Titan…
www.argex.ca/images/pdf/en/Presentation/Argex_IR_Presentatio…
"MONTREAL, April 9, 2015 /CNW Telbec/ - Argex Titanium, Inc. (RGX.TO), an emerging producer of high-grade titanium dioxide (TiO2) used as white pigment in paint, plastic, paper, cosmetics and other applications, announced that it has filed its financial results for the year ended December 31, 2014 on www.sedar.com and provided updated estimates related to the construction and operation of its first commercially sized TiO2 production facility to be located in Salaberry-de-Valleyfield, Quebec (the "Plant").
"During 2014, we achieved significant milestones including securing an exclusive long-term marketing and supply agreement with Helm U.S. Corp.," stated Roy Bonnell, President and CEO. "We raised CAD $7.5 million through the issuance of convertible debentures and exited 2014 with a clean capital structure as all remaining warrants have been exercised or expired."
"Furthermore, in December of 2014 Argex received an ICIS Innovation Award. The annual ICIS Innovation Awards recognizes chemical companies that demonstrate an innovative approach to business, the environment and/or sustainability. We are proud to be counted among the very best innovators," he added.
In February 2015, Argex announced that it had successfully completed technical due diligence associated with the financing of Argex's first Plant.
"We are pleased to have passed this major financing milestone," stated Roy Bonnell. "The technical diligence was demanding and thorough and contributed positively to the development of our financing process and our strategy of risk mitigation. Argex is poised for the next phase of its growth – the successful construction and operation of its first Plant."
Plant Operating Model
Argex has updated its target Plant operating model (the "Model") based on prevailing North American TiO2 prices and information gathered in connection with the technical due diligence process conducted by its potential financial sponsors, from marketing partners, internal estimates, equipment providers, and other third parties.
The following is a summary of Argex's Model based on the assumption of scale-up to full capacity. Argex currently estimates that full capacity of the Plant will be achieved approximately 12 months after commencement of commercial operations.
Argex's Plant Target Operating Model (in US Dollars):
- Worldwide TiO2 Market – 5.7 million tonnes / year
- Plant Capacity – 50,000 tonnes / year
- Revenue – $145 million to $155 million
- Gross Profit – $80 million to $96 million
- Gross Margin – 55% to 62%
- EBITDA – $65 million - $81 million
- EBITDA Margin – 45% to 52%
The Model referenced above is based on a number of assumptions and variables, such as product and by-product selling prices, product quality, ore selection, production yields, input costs, shipping costs, feedstock and chemicals costs, overhead costs, product mix, staffing estimates, foreign exchange rates and other inputs, all of which may be subject to change.
For information regarding the non-IFRS financial measures discussed in this release, please see "Non-IFRS Financial Measures" below.
Construction of Plant in Valleyfield Port Area
In its 2015 budget, the Quebec Government announced its plans to allocate CAD $1.5 billion to support its maritime strategy, including CAD $450 million to attract private investment by focusing on logistical and port infrastructure.
Argex has now secured a one million square foot parcel of land where it plans to build a customized building rather than to renovate and modify the existing building where Argex's pilot plant will continue to be situated. The parcel of land to be purchased from and rezoned by the City of Valleyfield, is located in the Valleyfield Port area and is expected to result in the following advantages as compared to the previously proposed site:
- Equivalent capital cost (including contingency risks), reduced construction risk as the potential for unknown liabilities and requirements to tear down, move or expand buildings and fixtures, are avoided.
- Increased building height and equipment layout flexibility.
- Closer proximity, with a rail spur easement, to a local CSX rail terminal and to the Port of Valleyfield.
- Closer proximity to a major chemical feedstock provider.
- Reduced operating expense.
- No change in construction timeline.
Non-IFRS financial measures
To supplement Argex's financial information presented in accordance with international financial reporting standards, or IFRS, Argex considers certain financial measures in evaluating its operating results and for financial and operational decision-making purposes. Financial measures not standardized under IFRS used by the Corporation, in this regard, such as earnings before interest, income taxes, depreciation and amortization (EBITDA), are not calculated in accordance with or recognized by IFRS. EBITDA should not be considered as an alternative to net income in measuring Argex's performance, nor should it be used as a measure of cash flow. EBITDA as calculated by Argex is equivalent to operating revenues less total operating, selling, general and administrative, and research and development costs. The Corporation's method of calculating these non-IFRS financial measures may differ from the methods used by other companies and, as a result, the non-IFRS financial measures presented in this document may not be comparable to other similarly titled measures disclosed by other companies. Argex's target Plant operating Model references EBITDA, a non-IFRS measure. EBITDA is calculated as net earnings before interest, depreciation, amortization and taxes, the "Reconciling Items". The Company is currently unable to provide a reconciliation to net income or loss as the amounts of the reconciling items, and in particular interest costs, associated with the Plant, are currently inestimable.
About Argex Titanium
Argex Titanium Inc. has developed an advanced chemical process for the volume production of high grade titanium dioxide (TiO2) for use in high quality paint, plastics, cosmetics and other applications. The Company's unique proprietary process takes relatively inexpensive and plentiful source material from a variety of potential vendors, and produces TiO2 along with other valuable by-products. Argex's process provides a significant cost and environmental advantage over current legacy TiO2 production methods. The Company's primary near term goal is to rapidly advance toward a 50,000 tonne per annum production module as a first step in its goal to transform the 5.7 million tonne per annum TiO2 industry. "
Antwort auf Beitrag Nr.: 49.565.000 von Popeye82 am 15.04.15 06:35:08
Highfield Resources Completes Positive K62 Potash Scoping Study, for Muga Mine By-Products; Anthony Hall: "This Scoping Study 'presents an opportunity for us, to benefit from the by-products of the Muga Mine'. It is 'an option that will ultimately deliver additional production volumes, +revenues, to the Muga operations, once the initial operations are able to support its development from free cash flow'." - May 1, 2015
Scoping Study outlines:
- Post tax, unlevered NPV10 of US$222,000,000
- Post tax, unlevered IRR of 33,0%
- EBITDA, in 1st full year of production, of US$56,000,000
+ Initial 24-year operational life, based on current DFS life of Muga Mine
+ Proposed installation of a conventional crystallisation plant, to treat slimes tailings, produced by the Muga Mine’s flotation processing plant
+ Average yearly production of ~135k tonnes of granular K62 potash, +a by-product of ~260k tonnes of high-purity vacuum salt
+ Capital cost estimated @US$124,000,000, inclusive of 20% contingency
+ Operating margins of ~65%, in full production
http://highfield.geoalcali.com/wp-content/uploads/sites/2/20…
http://highfield.geoalcali.com/wp-content/uploads/sites/2/20…
www.highfieldresources.com.au/wp-content/uploads/sites/2/201…
www.highfieldresources.com.au/wp-content/uploads/sites/2/201…
Highfield Resources Completes Positive K62 Potash Scoping Study, for Muga Mine By-Products; Anthony Hall: "This Scoping Study 'presents an opportunity for us, to benefit from the by-products of the Muga Mine'. It is 'an option that will ultimately deliver additional production volumes, +revenues, to the Muga operations, once the initial operations are able to support its development from free cash flow'." - May 1, 2015
Scoping Study outlines:
- Post tax, unlevered NPV10 of US$222,000,000
- Post tax, unlevered IRR of 33,0%
- EBITDA, in 1st full year of production, of US$56,000,000
+ Initial 24-year operational life, based on current DFS life of Muga Mine
+ Proposed installation of a conventional crystallisation plant, to treat slimes tailings, produced by the Muga Mine’s flotation processing plant
+ Average yearly production of ~135k tonnes of granular K62 potash, +a by-product of ~260k tonnes of high-purity vacuum salt
+ Capital cost estimated @US$124,000,000, inclusive of 20% contingency
+ Operating margins of ~65%, in full production
http://highfield.geoalcali.com/wp-content/uploads/sites/2/20…
http://highfield.geoalcali.com/wp-content/uploads/sites/2/20…
www.highfieldresources.com.au/wp-content/uploads/sites/2/201…
www.highfieldresources.com.au/wp-content/uploads/sites/2/201…
Lesezeichen
Antwort auf Beitrag Nr.: 49.694.250 von Mietzi543 am 02.05.15 13:50:31
hallo Mietzi,
ich würd gern mal noch die, wirren , Gedanken formulieren, die ich damit -Margen- auch verbinde
wei auch von erweitern und so gesprochen
täte mich mal interessieren was Du/Ihr dann dazu sagt
hallo Mietzi,
ich würd gern mal noch die, wirren , Gedanken formulieren, die ich damit -Margen- auch verbinde
wei auch von erweitern und so gesprochen
täte mich mal interessieren was Du/Ihr dann dazu sagt
WaferGen Biosystems -ein weiterer Kandidat
so eine "next gen tech" Firma
der CEO hat davon gesprochen dass er denkt sie BEI entsprechender Skalierung gross Margen von um die 80, 90% erreichen könn(t)en
bis jetzt machen sie keine Gewinne
aber die Firma hat -allein- in den letzten 3 Meldungen Vereinbarungen mit 2 der größten Firmen der Welt verkündet, insofern gibt es dem sicher schon eine gewisse Untermauerung
http://content.stockpr.com/wafergen/media/64a94d19155b7f986c…
https://lifesci.bluematrix.com/sellside/EmailDocViewer?encry…
http://financials.morningstar.com/ratios/r.html?t=WGBS®io…
eine meiner watchlist Firmen
weitere Informationen können hier entnommen werden , @15:45:08 Uhr
www.wallstreet-online.de/diskussion/1137033-33851-33860/news…
so eine "next gen tech" Firma
der CEO hat davon gesprochen dass er denkt sie BEI entsprechender Skalierung gross Margen von um die 80, 90% erreichen könn(t)en
bis jetzt machen sie keine Gewinne
aber die Firma hat -allein- in den letzten 3 Meldungen Vereinbarungen mit 2 der größten Firmen der Welt verkündet, insofern gibt es dem sicher schon eine gewisse Untermauerung
http://content.stockpr.com/wafergen/media/64a94d19155b7f986c…
https://lifesci.bluematrix.com/sellside/EmailDocViewer?encry…
http://financials.morningstar.com/ratios/r.html?t=WGBS®io…
eine meiner watchlist Firmen
weitere Informationen können hier entnommen werden , @15:45:08 Uhr
www.wallstreet-online.de/diskussion/1137033-33851-33860/news…
Osprey Medical, ein weiterer Kandidat
eine, von 2, Firmen wo ich im Moment fortgeschritten drüber nachdenke, als nächsten Kauf
wenn einige Dinge gutgehen mit Aussichten auf eine seeehr große cash cow
FDA Erlaubnis für Ihr Gerät ist schon vorhanden, zumindest die Standardversion
wer will, dem kann ich auch die kompletten (Cana)reports geben
http://stocknessmonster.com/news-item?S=OSP&E=ASX&N=420734
www.ospreymed.com/pdf/analyst/Canaccord_April_24_2015.pdf
eine, von 2, Firmen wo ich im Moment fortgeschritten drüber nachdenke, als nächsten Kauf
wenn einige Dinge gutgehen mit Aussichten auf eine seeehr große cash cow
FDA Erlaubnis für Ihr Gerät ist schon vorhanden, zumindest die Standardversion
wer will, dem kann ich auch die kompletten (Cana)reports geben
http://stocknessmonster.com/news-item?S=OSP&E=ASX&N=420734
www.ospreymed.com/pdf/analyst/Canaccord_April_24_2015.pdf
Actinium Pharmaceuticals, ein weiterer Kandidat
mit möglicherweise ROhmargen jenseits der 70%
wenn sie Ihr(e) (Krebs)Mittel genehmigt bekommen
www.redchip.com/assets/reports/ATNM_ResearchProfile_20140916…
https://lifesci.bluematrix.com/sellside/EmailDocViewer?encry…
www.edisoninvestmentresearch.com/serve_pdf.php?d=researchrep…
www.bestwallstreetpick.com/images/files/Laidlaw-Actinium-Ini…
mit möglicherweise ROhmargen jenseits der 70%
wenn sie Ihr(e) (Krebs)Mittel genehmigt bekommen
www.redchip.com/assets/reports/ATNM_ResearchProfile_20140916…
https://lifesci.bluematrix.com/sellside/EmailDocViewer?encry…
www.edisoninvestmentresearch.com/serve_pdf.php?d=researchrep…
www.bestwallstreetpick.com/images/files/Laidlaw-Actinium-Ini…
ein weiterer Kandidat
Applied DNA Sciences - Maxim Group Initiates Coverage, 'APDN’s DNA-Based Products are Effective, +'Likely to Disrupt the Anti-Counterfeiting, +Authentication, Markets' ' - Jan 12, 2015
- Brian Kinstlinger, CFA -
- Summary
+ Initiating coverage of APDN, a provider of botanical DNA-based anti-counterfeiting +authentication solutions, ...
+ The anti-counterfeiting market is 'estimated' @~$66,000,000,000, by Markets +Markets,+weee 'believe APDN’s DNA-based solution is more effective than the traditional technologies, +is unmatched in the market'.
+ APDN has 8 to 10 pilot programs, that 'have the 'potential' to 'exponentially' increase revenue, +drive profitability'.
+ We 'expect a retailer, or producer, of plastic will be the early adopter, +theeen the entire supply chain will 'likely be pressured, to adopt DNA marking'.'
+ Several 'key wins' within the federal government are establishing APDN, as a 'trusted federal partner', +will add a 'much-needed recurring revenue base' ...-
bkinstlinger@maximgrp.com
(212)895-3578
www.maximgrp.com/wp-content/uploads/2015/02/APDN-Initiation.…
http://scr.zacks.com/files/May-12-2015_APDN_Zeng_v001_j760b0…
Applied DNA Sciences - Maxim Group Initiates Coverage, 'APDN’s DNA-Based Products are Effective, +'Likely to Disrupt the Anti-Counterfeiting, +Authentication, Markets' ' - Jan 12, 2015
- Brian Kinstlinger, CFA -
- Summary
+ Initiating coverage of APDN, a provider of botanical DNA-based anti-counterfeiting +authentication solutions, ...
+ The anti-counterfeiting market is 'estimated' @~$66,000,000,000, by Markets +Markets,+weee 'believe APDN’s DNA-based solution is more effective than the traditional technologies, +is unmatched in the market'.
+ APDN has 8 to 10 pilot programs, that 'have the 'potential' to 'exponentially' increase revenue, +drive profitability'.
+ We 'expect a retailer, or producer, of plastic will be the early adopter, +theeen the entire supply chain will 'likely be pressured, to adopt DNA marking'.'
+ Several 'key wins' within the federal government are establishing APDN, as a 'trusted federal partner', +will add a 'much-needed recurring revenue base' ...-
bkinstlinger@maximgrp.com
(212)895-3578
www.maximgrp.com/wp-content/uploads/2015/02/APDN-Initiation.…
http://scr.zacks.com/files/May-12-2015_APDN_Zeng_v001_j760b0…
Antwort auf Beitrag Nr.: 49.690.935 von Popeye82 am 01.05.15 17:55:27
in meinem Hauptthread versaut er mir einige Formatierungen der "Serienposts", ich versteh nicht so richtig warum
k**zt mich auch so gaaanz leicht bisschen an
daher hier nochmal richtig
so war die aufgearbeitet
Highfield Resources adds large exploration target, to Muga mine life - PAI, AU - Jun 19, 2015
http://highfield.geoalcali.com/wp-content/uploads/sites/2/20…
www.proactiveinvestors.com.au/companies/news/63014/highfield…
http://highfield.geoalcali.com/wp-content/uploads/sites/2/20…
http://highfield.geoalcali.com/wp-content/uploads/sites/2/20…
www.highfieldresources.com.au/pdfs/2014AnnualReport10Sep14.p…
http://financials.morningstar.com/ratios/r.html?t=HFR®ion…
"Highfield Resources (ASX:HFR) has added a large Exploration Target for the north western extension of its flagship Muga Potash Project in Spain that could add substantial scale and mine life.
The Exploration Target of 127 million to 255 million tonnes of sylvinite grading 12% to 16% K2O is based on geophysical surveys that demonstrate continuity of the potash bearing evaporite.
It also abuts the Vipasca Project which is around three times the size of the current Muga Project and Exploration Target.
Drilling of the Exploration Target, which covers just two of the five possible seams identified within the total project area, is expected to start in the fourth quarter of 2015.
- Highfield Resources adds large exploration target to Muga mine life -
Targeted commencement of Muga Mine construction remains on track for the fourth quarter of 2015 with the company receiving tenders from six construction companies for construction of the two declines. Another two tenders are expected.
“We are encouraged by the addition of this Exploration Target to the Muga Project,” managing director Anthony Hall said.
“Our focus remains commencing construction of the Muga Mine DFS project this year, and in the backdrop, it is important that we continue our exploration work to demonstrate the veracity of likely Muga Mine extensions and the additional four projects under our control.
“Our stated aim of becoming a significant global potash producer depends on the strength and measured development of our pipeline. We believe that ALL our projects are likely to be low capex, high margin long life mines – as we are proving our flagship Muga Project to be.”
In May, the company raised $101 million in a private placement priced at $1.80 to institutional and sophisticated investors in Australia, Asia, Europe and North America.
Exploration Target
The Exploration Target encompasses the Capa 1 and Capa 2 seams (two of five seams encountered across the Project) and excludes any of the other project areas contiguous with the Muga Project.
Highfield chose to exclude the Capa 0, Capa A and Capa B from the Exploration Target, though continuity could exist in these three seams, mainly the Capa B.
These seams do not appear to be as thick nor as high grade as the Capa 1 and Capa 2.
Muga Potash Project
The flagship Muga Potash Project in northern Spain is targeting the relatively shallow sylvinite beds that cover an area of around 80 square kilometres.
Mineralisation commences at depths from surface of less than 200 metres and appears ideal for a relatively low-cost conventional mine accessed via a dual decline as demonstrated in the company’s DFS that was completed in March 2015.
Highfield is proceeding with detailed design and engineering and other development and contracting work preparatory to full site construction start after final permitting expected later in 2015.
A total of 38 exploration drill holes (11 historic, 27 completed by Highfield Resources) have been completed within the Project area, providing a high level of confidence with respect to continuity of the evaporite horizon, decline access and mineralisation grade across the ore body.
Analysis
Highfield Resources’ Exploration Target in the northwestern area of the Muga Project has the potential to add to the existing mine life of 24 years at a production rate of 1.13 million tonnes of potash per annum.
Using a midpoint of around 190 million tonnes at 14%K2O and assuming that circa 60% converts to a Reserve, this could add a hefty 20 years to the Muga mine life.
Interestingly, the Exploration Target area abuts the Vipasca Project which is around three times the size of the current Muga Project and Exploration Target.
This creates a further level of upside in the Highfield valuation with Vipasca, which could be a project with similar or larger metrics to the Muga Project.
Muga is just one of five potash projects that Highfield holds in Spain.
Highfield remains on track to start construction of the Muga Mine in the fourth quarter of this year with tenders received from six construction companies and another two tenders expected.
Profile
Highfield Resources (ASX:HFR) is an ASX-Listed potash company with four 100% owned projects located in Spain. "
in meinem Hauptthread versaut er mir einige Formatierungen der "Serienposts", ich versteh nicht so richtig warum
k**zt mich auch so gaaanz leicht bisschen an
daher hier nochmal richtig
so war die aufgearbeitet
Highfield Resources adds large exploration target, to Muga mine life - PAI, AU - Jun 19, 2015
http://highfield.geoalcali.com/wp-content/uploads/sites/2/20…
www.proactiveinvestors.com.au/companies/news/63014/highfield…
http://highfield.geoalcali.com/wp-content/uploads/sites/2/20…
http://highfield.geoalcali.com/wp-content/uploads/sites/2/20…
www.highfieldresources.com.au/pdfs/2014AnnualReport10Sep14.p…
http://financials.morningstar.com/ratios/r.html?t=HFR®ion…
"Highfield Resources (ASX:HFR) has added a large Exploration Target for the north western extension of its flagship Muga Potash Project in Spain that could add substantial scale and mine life.
The Exploration Target of 127 million to 255 million tonnes of sylvinite grading 12% to 16% K2O is based on geophysical surveys that demonstrate continuity of the potash bearing evaporite.
It also abuts the Vipasca Project which is around three times the size of the current Muga Project and Exploration Target.
Drilling of the Exploration Target, which covers just two of the five possible seams identified within the total project area, is expected to start in the fourth quarter of 2015.
- Highfield Resources adds large exploration target to Muga mine life -
Targeted commencement of Muga Mine construction remains on track for the fourth quarter of 2015 with the company receiving tenders from six construction companies for construction of the two declines. Another two tenders are expected.
“We are encouraged by the addition of this Exploration Target to the Muga Project,” managing director Anthony Hall said.
“Our focus remains commencing construction of the Muga Mine DFS project this year, and in the backdrop, it is important that we continue our exploration work to demonstrate the veracity of likely Muga Mine extensions and the additional four projects under our control.
“Our stated aim of becoming a significant global potash producer depends on the strength and measured development of our pipeline. We believe that ALL our projects are likely to be low capex, high margin long life mines – as we are proving our flagship Muga Project to be.”
In May, the company raised $101 million in a private placement priced at $1.80 to institutional and sophisticated investors in Australia, Asia, Europe and North America.
Exploration Target
The Exploration Target encompasses the Capa 1 and Capa 2 seams (two of five seams encountered across the Project) and excludes any of the other project areas contiguous with the Muga Project.
Highfield chose to exclude the Capa 0, Capa A and Capa B from the Exploration Target, though continuity could exist in these three seams, mainly the Capa B.
These seams do not appear to be as thick nor as high grade as the Capa 1 and Capa 2.
Muga Potash Project
The flagship Muga Potash Project in northern Spain is targeting the relatively shallow sylvinite beds that cover an area of around 80 square kilometres.
Mineralisation commences at depths from surface of less than 200 metres and appears ideal for a relatively low-cost conventional mine accessed via a dual decline as demonstrated in the company’s DFS that was completed in March 2015.
Highfield is proceeding with detailed design and engineering and other development and contracting work preparatory to full site construction start after final permitting expected later in 2015.
A total of 38 exploration drill holes (11 historic, 27 completed by Highfield Resources) have been completed within the Project area, providing a high level of confidence with respect to continuity of the evaporite horizon, decline access and mineralisation grade across the ore body.
Analysis
Highfield Resources’ Exploration Target in the northwestern area of the Muga Project has the potential to add to the existing mine life of 24 years at a production rate of 1.13 million tonnes of potash per annum.
Using a midpoint of around 190 million tonnes at 14%K2O and assuming that circa 60% converts to a Reserve, this could add a hefty 20 years to the Muga mine life.
Interestingly, the Exploration Target area abuts the Vipasca Project which is around three times the size of the current Muga Project and Exploration Target.
This creates a further level of upside in the Highfield valuation with Vipasca, which could be a project with similar or larger metrics to the Muga Project.
Muga is just one of five potash projects that Highfield holds in Spain.
Highfield remains on track to start construction of the Muga Mine in the fourth quarter of this year with tenders received from six construction companies and another two tenders expected.
Profile
Highfield Resources (ASX:HFR) is an ASX-Listed potash company with four 100% owned projects located in Spain. "
vermutlich eine margenstarke firma
Mitua Group - lists on ASX, with $153,700,000 market capitalisation - Jul 1, 2015
http://stocknessmonster.com/news-item?S=MUA&E=ASX&N=425650
Mitua Group - lists on ASX, with $153,700,000 market capitalisation - Jul 1, 2015
http://stocknessmonster.com/news-item?S=MUA&E=ASX&N=425650
ein weiterer Kandidat -United Cacao
unter Umständen könnte das in ein paar jahren eine sehr hochmargige firma sein, mit dann vielleicht EBIDTA margen in der 60% region
1. link um 7:27uhr
www.wallstreet-online.de/diskussion/1137033-34571-34580/news…
www.hardmanandco.com/sites/default/files/research_papers/UCL…
www.unitedcacao.com/images/downloads/investor-presentations/…
unter Umständen könnte das in ein paar jahren eine sehr hochmargige firma sein, mit dann vielleicht EBIDTA margen in der 60% region
1. link um 7:27uhr
www.wallstreet-online.de/diskussion/1137033-34571-34580/news…
www.hardmanandco.com/sites/default/files/research_papers/UCL…
www.unitedcacao.com/images/downloads/investor-presentations/…
Aber nur dann, wenn die Kakaopreise anziehen. Dieses Jahr ist das bislang der Fall. Kakao ist aber, soweit ich weiss, ein hochsensibles Produkt. Langfristig scheint mir UC weniger geeignet, denn als Zock auf die Kakaopreisentwicklung.
Die Aktie ist ausserdem selbst in London recht markteng.
Ein Kakaoproduzent ist zwar interessant auf dem Kurszettel. So richtig überzeugt mich das aber noch nicht.
Die Aktie ist ausserdem selbst in London recht markteng.
Ein Kakaoproduzent ist zwar interessant auf dem Kurszettel. So richtig überzeugt mich das aber noch nicht.
Antwort auf Beitrag Nr.: 50.090.199 von sdaktien am 01.07.15 13:54:52
muss dich nicht überzeugen, jeder wie er will
ohne eine genauere bewertung vorzunehmen, würde ich mich deinem fazit aber eher nicht anschliessen
ALLEIN die STeuer(wegfall) ist huge(!!), und ein ganz direkt greifbar finanzieller Vorteil
muss dich nicht überzeugen, jeder wie er will
ohne eine genauere bewertung vorzunehmen, würde ich mich deinem fazit aber eher nicht anschliessen
ALLEIN die STeuer(wegfall) ist huge(!!), und ein ganz direkt greifbar finanzieller Vorteil
Um Steuer bezahlen zu können, müssen Gewinne her, dazu muss der Kakaopreis hoch sein. Momentan ist er das, ja, aber keiner kann sagen, wie es in einigen Jahren sein wird. Was ich nicht gelesen habe, vielleicht habe ich es ja überlesen: Wie hoch muss der Kakaopreis sein um Verluste zu vermeiden?!
Antwort auf Beitrag Nr.: 49.601.702 von Popeye82 am 20.04.15 13:35:49
presentation, dokumente etc. zu
"2nd largest citrus fruits harvester in China"
https://gallery.mailchimp.com/22b7ac13fc0d89cedaab1dec6/file…
https://gallery.mailchimp.com/22b7ac13fc0d89cedaab1dec6/file…
http://paradigmsecurities.com.au/wp-content/uploads/DFM-PROS…
Dongfang Modern Agricultural Holding Group Ltd (ASXFM)
"Dongfang Modern Agricultural Holding Group Ltd is a leading grower/harvester of citrus and other products in Ganzhou City district of Jiangxi Province in China.
Prominent and very profitable grower and harvester of citrus produce in PRC
Extraordinary operating history over more than six years.
ASX IPO Raising up to A$50m in A$400m listing.
IPO open now and closing 7 August 2015
Paradigm Securities Lead Manager
7 February
The Company has a remarkable history of revenue and earnings growth and is seeking additional capital through a proposed listing on ASX through a Prospectus that would raise a minimum of A$39m and a maximum of A$50m at an Issue Price of A$1.00 per Share.
The Company sells over 200,000 tonnes of tangerines, pomelos and navel oranges and camellia fruit products to generate revenue of a forecast +A$170m and earnings of about A$75m in calendar 2015.
The Company is debt free and has net assets of over A$215m including A$56m in cash and with the current 351m shares on issue has a pre IPO value of A$351m which is about 5.0 times forecast Calendar 2015 earnings.
Dongfang Modern is an aggregator of plantations in Jiangxi Province and has successfully acquired over 8500 hectares in 19 plantations mostly in the Ganzhou City district.
Ganzhou is regarded as producing China’s finest citrus fruit from orchards in high rainfall hilly topography.
Consolidating fragmented plantations and marketing the produce through high volume outlets in the major Chinese cities generates high operating margins of over 40% and the Company sees long term further growth as China’s 1,400 people increase demand for fruit with rising personal incomes. "
presentation, dokumente etc. zu
"2nd largest citrus fruits harvester in China"
https://gallery.mailchimp.com/22b7ac13fc0d89cedaab1dec6/file…
https://gallery.mailchimp.com/22b7ac13fc0d89cedaab1dec6/file…
http://paradigmsecurities.com.au/wp-content/uploads/DFM-PROS…
Dongfang Modern Agricultural Holding Group Ltd (ASXFM)
"Dongfang Modern Agricultural Holding Group Ltd is a leading grower/harvester of citrus and other products in Ganzhou City district of Jiangxi Province in China.
Prominent and very profitable grower and harvester of citrus produce in PRC
Extraordinary operating history over more than six years.
ASX IPO Raising up to A$50m in A$400m listing.
IPO open now and closing 7 August 2015
Paradigm Securities Lead Manager
7 February
The Company has a remarkable history of revenue and earnings growth and is seeking additional capital through a proposed listing on ASX through a Prospectus that would raise a minimum of A$39m and a maximum of A$50m at an Issue Price of A$1.00 per Share.
The Company sells over 200,000 tonnes of tangerines, pomelos and navel oranges and camellia fruit products to generate revenue of a forecast +A$170m and earnings of about A$75m in calendar 2015.
The Company is debt free and has net assets of over A$215m including A$56m in cash and with the current 351m shares on issue has a pre IPO value of A$351m which is about 5.0 times forecast Calendar 2015 earnings.
Dongfang Modern is an aggregator of plantations in Jiangxi Province and has successfully acquired over 8500 hectares in 19 plantations mostly in the Ganzhou City district.
Ganzhou is regarded as producing China’s finest citrus fruit from orchards in high rainfall hilly topography.
Consolidating fragmented plantations and marketing the produce through high volume outlets in the major Chinese cities generates high operating margins of over 40% and the Company sees long term further growth as China’s 1,400 people increase demand for fruit with rising personal incomes. "
eine der vermutlich klassisch(st?)en hochmargigen firmen,
betätigungsfeld muss wohl nicht erklärt werden
Visa
http://financials.morningstar.com/ratios/r.html?t=V
betätigungsfeld muss wohl nicht erklärt werden
Visa
http://financials.morningstar.com/ratios/r.html?t=V
fällt wieder unter Kandidat
Bee Vectoring Technologies,
ziemlich speziell was sie machen,
sollte man ggf. mal selber ein bisschen schauen
AB einer gewissen erreichten Größenordnung
halten sie 70% rohertragsmargin für möglich
prinzipiell so ein ding genau nach meinem geschmack
hier werde ich event. noch mehr recherchieren
www.equities.com/spotlight/spotlight-companies/revolutionizi…
http://beevt.com/wp/?page_id=11017
www.bnn.ca/Video/player.aspx?vid=707560
www.bnn.ca/Video/player.aspx?vid=650660
http://sedar.com/CheckCode.do
Bee Vectoring Technologies,
ziemlich speziell was sie machen,
sollte man ggf. mal selber ein bisschen schauen
AB einer gewissen erreichten Größenordnung
halten sie 70% rohertragsmargin für möglich
prinzipiell so ein ding genau nach meinem geschmack
hier werde ich event. noch mehr recherchieren
www.equities.com/spotlight/spotlight-companies/revolutionizi…
http://beevt.com/wp/?page_id=11017
www.bnn.ca/Video/player.aspx?vid=707560
www.bnn.ca/Video/player.aspx?vid=650660
http://sedar.com/CheckCode.do
Antwort auf Beitrag Nr.: 50.157.357 von Popeye82 am 10.07.15 11:08:01
Listing of Dongfang Modern, 11 am Mon, 19 Oct '15
- A$39.2m raised in A$390m market cap IPO
- DFM.ASX is one of China’s largest growers/harvesters of citrus produce
- Produce sales expected to be 15% higher in 2015 at 230,000 tonnes
- Harvest season providing all DFM income now underway in Dec Qtr
- Prospectus forecast give A$75m earnings (EPS A$0.19) and PER <5.5x
- Cash balance of A$80m rising to A$150m (pre acquisitions) by end Dec 2015
- China consumer goods demand still growing strongly
- Excellent long term growth prospects
http://paradigmsecurities.com.au/listing-of-dongfang-modern-…
"Dongfang Modern has successfully met its ASX listing conditions and should now provide an outstanding opportunity for Australia investors to participate in the rising affluence of China’s middle classes. Rising personal incomes and increasing health consciousness are driving the demand for nutritious, clean, safe and enjoyable foodstuffs like oranges, tangerines and lemons and these secular trends are likely to last for decades. DFM is very well positioned for this growth.
Recent data from China continues to show strong growth in demand for such produce and prices are still quite firm.
So much data from China continues to show a growing and resilient economy.
Imports of crude oil for China are up 8.6% year to date and iron ore imports rate in September was well over 1 billion tonnes (1047mtpa) after 932mt total imports in 2014. Just to show you that the China collapse story doesn’t quite hold true.
This recent graphic from Goldman Sachs divides China consumption trends into Opex and Capex. Not so much new construction capex (although infrastructure spending is still very robust).
You can draw some very interesting conclusions here about sector rotation.
So when looking at Dongfang Modern here is what you find.
First of all I hope you expect that the Due Diligence carried out on this company is of a high standard. The Legals were overseen by Piper Alderman and the accounts were reviewed by PKF Lawyers. The accounts have been audited since 2009 by PKF Hong Kong so the data is reliable. The cash on the balance sheet is actually there!
I have made mention previously that this has to be the most impressive set of accounts I have seen in my +30 years.
This company was set up in 2005 and in 2008 the current Chairman injected about US$6m to acquire an 89% holding.
This was the last capital injection to the company. No more equity and no debt at all.
The plan was to acquire as many plantations as possible and by 2012 it was 9 plantations over 4500 hectares and by end 2015 it will be 19 plantations over 9,000 hectares.
That initial investment of US$6m in 2008 has probably provided the highest multiyear IRR ever recorded. After A$57m (A$ equivalent) earnings in 2014 DFM’s June 2015 Interim showed Retained Earnings of A$216m. All done without additional equity capital and without debt.
These numbers are attractive and make interesting reading. 2015 and pre 2015 are PKF numbers and the forecasts post 2015 are Dawes Points alone.
The company is now probably the largest citrus grower/harvester in China with about 1.3% market share by revenue in a very fragmented industry. So many industries in China seem to be highly fragmented and the aggregation and consolidation process there has probably twenty years more to run. These are important business drivers and help to show another side of China.
Paradigm carried out major financial due diligence and modelling and made a site visit to several of the plantations.
Detailed forecasts were made based on all available published information and then some conservative assumptions were made.
Growing and harvesting citrus produce isn’t all that far from something like coal mining.
You have a resource (trees) that should give a certain grade (harvest) with output of net fruit (grade) and at an expected recovery (yield). The selling price is the market price so revenue is saleable output time’s price. Costs are roughly fixed so improved yields and productivity improvements can increase volume without fixed costs rising. Dongfang is hoping improve yields by about 4-5% pa for the next few years. So output should rise and costs rise less so.
Output will also rise as additional plantations are acquired.
Prices have been rising over the past few years too because demand has been stronger than supply and supply growth.
Dongfang’s operating margin has been over 40% for the past few years and it expects to will stay high.
A study of future earnings for the next decade based on increasing tree volume through plantation acquisition, rising labour cost (which they are doing), modestly improving harvest yields and marginally higher product prices gave some quite astounding numbers.
Dongfang was #2 by sales revenue in 2014 with 1.2% market share after AIM listed Asiatic Citrus but the increased output to 230,000tpa in 2015 by Dongfang coupled with a couple of operational issues for Asiatic Citrus should now make DFM #1 with about 1.3% market share.
Market leader with 1.3% market share reinforces this fragmented industry concept.
Dongfang would like to go to 4-5% market share over the next several years so that implies organic and acquisitional growth
The numbers for Dongfang as assessed from public information by Dawes Points look like this with historic data in RMB and converted to A$ at historic rates or using the IPO Prospectus forecast of RMB 5:A$1.00.
This Valuation Matrix shows DFM’s P&L and Balance Sheet in one and also gives a valuation target for DFM.
Note three years earnings history, the current year estimate and three years forecast for EBITDA on a product basis (note the very low D&A levels) and no interest cost.
Forecasts are deliberately conservative on prices, output, acquisition growth and costs but still show earnings rising steadily rather than surging.
The staff levels are low (only about 100 people) so administration expense is low and all harvesting is by contractors so EBITDA for each product is net cash. Note no tax is payable on earnings from agricultural food production and that almost all earnings have been reinvested, with capex mostly into acquisition of additional plantations.
The balance sheet is cash-rich without debt and EBITDA against estimates of sector assets gives a Return on Investment (on book value) of 30% overall and almost 100% for tangerines.
If we put each product division on 5x EBITDA, and add the cash, the appraised value for DFM is over A$500m and A$1.47/share compared to the IPO price of A$1.00.
Note that the forecasts have used 5:1 on the exchange rate, well above the current level, so A$ earnings would be higher with today’s 4.62:1.
I expect over time that the market will give a much higher rating after DFM delivers on its plans.
The Chinese Equity Market
The recent volatility in the Shanghai Index had many calling for the end of China.
The commentary had conveniently ignored that China’s equity markets had declined a total of 65% over 7 years whilst its economy more than doubled. The 150% rise in less than a year seems quite modest compared to previous surges.
Dongfang Modern is one of the largest China operations listed on ASX and shouldn’t be the last.
If you came into the IPO, (and thanks for your help), you probably only came in in a modest contribution.
If you haven’t, the hard work has been done so you should now be able to come in at lower entry risk to share the gains.
Barry Dawes
19 October 2015
I own DFM and Paradigm was the lead manager of the DFM IPO.
Edition #42 "
Listing of Dongfang Modern, 11 am Mon, 19 Oct '15
- A$39.2m raised in A$390m market cap IPO
- DFM.ASX is one of China’s largest growers/harvesters of citrus produce
- Produce sales expected to be 15% higher in 2015 at 230,000 tonnes
- Harvest season providing all DFM income now underway in Dec Qtr
- Prospectus forecast give A$75m earnings (EPS A$0.19) and PER <5.5x
- Cash balance of A$80m rising to A$150m (pre acquisitions) by end Dec 2015
- China consumer goods demand still growing strongly
- Excellent long term growth prospects
http://paradigmsecurities.com.au/listing-of-dongfang-modern-…
"Dongfang Modern has successfully met its ASX listing conditions and should now provide an outstanding opportunity for Australia investors to participate in the rising affluence of China’s middle classes. Rising personal incomes and increasing health consciousness are driving the demand for nutritious, clean, safe and enjoyable foodstuffs like oranges, tangerines and lemons and these secular trends are likely to last for decades. DFM is very well positioned for this growth.
Recent data from China continues to show strong growth in demand for such produce and prices are still quite firm.
So much data from China continues to show a growing and resilient economy.
Imports of crude oil for China are up 8.6% year to date and iron ore imports rate in September was well over 1 billion tonnes (1047mtpa) after 932mt total imports in 2014. Just to show you that the China collapse story doesn’t quite hold true.
This recent graphic from Goldman Sachs divides China consumption trends into Opex and Capex. Not so much new construction capex (although infrastructure spending is still very robust).
You can draw some very interesting conclusions here about sector rotation.
So when looking at Dongfang Modern here is what you find.
First of all I hope you expect that the Due Diligence carried out on this company is of a high standard. The Legals were overseen by Piper Alderman and the accounts were reviewed by PKF Lawyers. The accounts have been audited since 2009 by PKF Hong Kong so the data is reliable. The cash on the balance sheet is actually there!
I have made mention previously that this has to be the most impressive set of accounts I have seen in my +30 years.
This company was set up in 2005 and in 2008 the current Chairman injected about US$6m to acquire an 89% holding.
This was the last capital injection to the company. No more equity and no debt at all.
The plan was to acquire as many plantations as possible and by 2012 it was 9 plantations over 4500 hectares and by end 2015 it will be 19 plantations over 9,000 hectares.
That initial investment of US$6m in 2008 has probably provided the highest multiyear IRR ever recorded. After A$57m (A$ equivalent) earnings in 2014 DFM’s June 2015 Interim showed Retained Earnings of A$216m. All done without additional equity capital and without debt.
These numbers are attractive and make interesting reading. 2015 and pre 2015 are PKF numbers and the forecasts post 2015 are Dawes Points alone.
The company is now probably the largest citrus grower/harvester in China with about 1.3% market share by revenue in a very fragmented industry. So many industries in China seem to be highly fragmented and the aggregation and consolidation process there has probably twenty years more to run. These are important business drivers and help to show another side of China.
Paradigm carried out major financial due diligence and modelling and made a site visit to several of the plantations.
Detailed forecasts were made based on all available published information and then some conservative assumptions were made.
Growing and harvesting citrus produce isn’t all that far from something like coal mining.
You have a resource (trees) that should give a certain grade (harvest) with output of net fruit (grade) and at an expected recovery (yield). The selling price is the market price so revenue is saleable output time’s price. Costs are roughly fixed so improved yields and productivity improvements can increase volume without fixed costs rising. Dongfang is hoping improve yields by about 4-5% pa for the next few years. So output should rise and costs rise less so.
Output will also rise as additional plantations are acquired.
Prices have been rising over the past few years too because demand has been stronger than supply and supply growth.
Dongfang’s operating margin has been over 40% for the past few years and it expects to will stay high.
A study of future earnings for the next decade based on increasing tree volume through plantation acquisition, rising labour cost (which they are doing), modestly improving harvest yields and marginally higher product prices gave some quite astounding numbers.
Dongfang was #2 by sales revenue in 2014 with 1.2% market share after AIM listed Asiatic Citrus but the increased output to 230,000tpa in 2015 by Dongfang coupled with a couple of operational issues for Asiatic Citrus should now make DFM #1 with about 1.3% market share.
Market leader with 1.3% market share reinforces this fragmented industry concept.
Dongfang would like to go to 4-5% market share over the next several years so that implies organic and acquisitional growth
The numbers for Dongfang as assessed from public information by Dawes Points look like this with historic data in RMB and converted to A$ at historic rates or using the IPO Prospectus forecast of RMB 5:A$1.00.
This Valuation Matrix shows DFM’s P&L and Balance Sheet in one and also gives a valuation target for DFM.
Note three years earnings history, the current year estimate and three years forecast for EBITDA on a product basis (note the very low D&A levels) and no interest cost.
Forecasts are deliberately conservative on prices, output, acquisition growth and costs but still show earnings rising steadily rather than surging.
The staff levels are low (only about 100 people) so administration expense is low and all harvesting is by contractors so EBITDA for each product is net cash. Note no tax is payable on earnings from agricultural food production and that almost all earnings have been reinvested, with capex mostly into acquisition of additional plantations.
The balance sheet is cash-rich without debt and EBITDA against estimates of sector assets gives a Return on Investment (on book value) of 30% overall and almost 100% for tangerines.
If we put each product division on 5x EBITDA, and add the cash, the appraised value for DFM is over A$500m and A$1.47/share compared to the IPO price of A$1.00.
Note that the forecasts have used 5:1 on the exchange rate, well above the current level, so A$ earnings would be higher with today’s 4.62:1.
I expect over time that the market will give a much higher rating after DFM delivers on its plans.
The Chinese Equity Market
The recent volatility in the Shanghai Index had many calling for the end of China.
The commentary had conveniently ignored that China’s equity markets had declined a total of 65% over 7 years whilst its economy more than doubled. The 150% rise in less than a year seems quite modest compared to previous surges.
Dongfang Modern is one of the largest China operations listed on ASX and shouldn’t be the last.
If you came into the IPO, (and thanks for your help), you probably only came in in a modest contribution.
If you haven’t, the hard work has been done so you should now be able to come in at lower entry risk to share the gains.
Barry Dawes
19 October 2015
I own DFM and Paradigm was the lead manager of the DFM IPO.
Edition #42 "
Antwort auf Beitrag Nr.: 50.876.997 von Popeye82 am 19.10.15 03:56:36Wo soll der Emissionspreis liegen?
Antwort auf Beitrag Nr.: 50.879.277 von sdaktien am 19.10.15 12:32:56
"If we put each product division on 5x EBITDA, and add the cash, the appraised value for DFM is over A$500m and A$1.47/share compared to the IPO price of A$1.00"
"If we put each product division on 5x EBITDA, and add the cash, the appraised value for DFM is over A$500m and A$1.47/share compared to the IPO price of A$1.00"
könnte evt. hierfür etwas werden
50% Auszahlung finde ich vollkommen bekloppt
Chorus Clean Energy -"Schöne Gewinne mit Sonne +Wind"
www.wallstreet-online.de/nachricht/8288565-egbert-prior-chor…
"Die Aktie hat im Oktober in einem schwierigen Börsenumfeld den Sprung auf das Parkett geschafft. Trotz der Turbulenzen an den Finanzmärkten, hält sich der Kurs wacker in der Nähe des Ausgabepreises (9,75 Euro). Aktuell 9,54 Euro. Im Gespräch mit der Prior Börse verweist Vorstandschef Holger Götze auf einen deutlichen Bewertungsabschlag zwischen 30 und 40% im Vergleich zum ebenfalls börsennotierten Wettbewerber Capital Stage.
Chorus Clean Energy betreibt aktuell 72 Solar- und Windparks in fünf europäischen Ländern. Außerdem betätigen sich die Münchener als Asset Manager und bieten institutionellen Investoren die Möglichkeit, sich direkt an Solar- oder Windparks zu beteiligen. Das IPO hat 100 Millionen Euro eingespielt. Das fresh money möchte CEO Götze nach Möglichkeit noch in diesem Jahr komplett investieren in weitere Anlagen zur Produktion Erneuerbarer Energien. Das würde zu einem Umsatz- und Gewinnsprung führen.
Eine Analystenstudie der Berenberg Bank geht beispielsweise davon aus, daß der Umsatz 2016 um rund 50% auf 95 Millionen Euro nach oben schießt, der Profit sogar um 60% auf 24 Millionen nach Steuern. Bemerkenswert die üppige Nettomarge in Höhe von ungefähr 25%. Die hohe Profitabilität erscheint um so erstaunlicher, als das Geschäft verhältnismäßig risikoarm ist. Wie Götze erläutert, investiert Chorus fast ausschließlich in Anlagen mit festgelegten Einspeisevergütungen, die rückwirkend nicht geändert werden können. Der Unternehmenslenker spricht von konjunkturunabhängigen, stabilen cash flows.
Neben dem Betrieb eigener Anlagen möchten die Münchener das Geschäft als Asset Manager ausbauen. Im Dezember kaufte Chorus für zwei deutsche Versorger einen Solar- und einen Windpark. Für Götze liegen die Vorteile des Asset Managements auf der Hand, es sei margenstark, binde kaum Kapital und sei weitgehend im Rahmen der vorhandenen Kapazitäten zu betreiben. Die Börse bewertet Chorus derzeit mit gut 260 Millionen Euro. Das KGV schätzungsweise elf. Günstig. Chorus dürfte sich auch zu einem attraktiven Dividendenwert entwickeln. Angedacht ist eine Ausschüttungsquote in Höhe von etwa 50%. Fazit: Attraktives und stabiles Geschäftsmodell. Die Aktie ist noch nicht ausgereizt. "
50% Auszahlung finde ich vollkommen bekloppt
Chorus Clean Energy -"Schöne Gewinne mit Sonne +Wind"
www.wallstreet-online.de/nachricht/8288565-egbert-prior-chor…
"Die Aktie hat im Oktober in einem schwierigen Börsenumfeld den Sprung auf das Parkett geschafft. Trotz der Turbulenzen an den Finanzmärkten, hält sich der Kurs wacker in der Nähe des Ausgabepreises (9,75 Euro). Aktuell 9,54 Euro. Im Gespräch mit der Prior Börse verweist Vorstandschef Holger Götze auf einen deutlichen Bewertungsabschlag zwischen 30 und 40% im Vergleich zum ebenfalls börsennotierten Wettbewerber Capital Stage.
Chorus Clean Energy betreibt aktuell 72 Solar- und Windparks in fünf europäischen Ländern. Außerdem betätigen sich die Münchener als Asset Manager und bieten institutionellen Investoren die Möglichkeit, sich direkt an Solar- oder Windparks zu beteiligen. Das IPO hat 100 Millionen Euro eingespielt. Das fresh money möchte CEO Götze nach Möglichkeit noch in diesem Jahr komplett investieren in weitere Anlagen zur Produktion Erneuerbarer Energien. Das würde zu einem Umsatz- und Gewinnsprung führen.
Eine Analystenstudie der Berenberg Bank geht beispielsweise davon aus, daß der Umsatz 2016 um rund 50% auf 95 Millionen Euro nach oben schießt, der Profit sogar um 60% auf 24 Millionen nach Steuern. Bemerkenswert die üppige Nettomarge in Höhe von ungefähr 25%. Die hohe Profitabilität erscheint um so erstaunlicher, als das Geschäft verhältnismäßig risikoarm ist. Wie Götze erläutert, investiert Chorus fast ausschließlich in Anlagen mit festgelegten Einspeisevergütungen, die rückwirkend nicht geändert werden können. Der Unternehmenslenker spricht von konjunkturunabhängigen, stabilen cash flows.
Neben dem Betrieb eigener Anlagen möchten die Münchener das Geschäft als Asset Manager ausbauen. Im Dezember kaufte Chorus für zwei deutsche Versorger einen Solar- und einen Windpark. Für Götze liegen die Vorteile des Asset Managements auf der Hand, es sei margenstark, binde kaum Kapital und sei weitgehend im Rahmen der vorhandenen Kapazitäten zu betreiben. Die Börse bewertet Chorus derzeit mit gut 260 Millionen Euro. Das KGV schätzungsweise elf. Günstig. Chorus dürfte sich auch zu einem attraktiven Dividendenwert entwickeln. Angedacht ist eine Ausschüttungsquote in Höhe von etwa 50%. Fazit: Attraktives und stabiles Geschäftsmodell. Die Aktie ist noch nicht ausgereizt. "
potenziell hochmargig -Mineral Commodities, eine Mineral Sands Firma in Südafrika
www.edisoninvestmentresearch.com/serve_pdf.php?d=researchrep…
www.edisoninvestmentresearch.com/serve_pdf.php?d=researchrep…
adjusted gross margin 73,4%,
Net Income "(knapp)neutral", noch
www.stockhouse.com/news/press-releases/2016/04/21/aphria-rep…
Net Income "(knapp)neutral", noch
www.stockhouse.com/news/press-releases/2016/04/21/aphria-rep…
von Kleiner Chef geklaut -Publity AG
eine deutsche Asset Management Firma, in Büroimmobilien
HJ1 Nettomarge >36(!)%
www.publity.de/de/investor/news-und-medien/publity-pressemel…
eine deutsche Asset Management Firma, in Büroimmobilien
HJ1 Nettomarge >36(!)%
www.publity.de/de/investor/news-und-medien/publity-pressemel…
EBay,
dieses Quartal Nettogewinnmarge >19/22% GAAP/non-GAAP, FCF 28%
https://finance.yahoo.com/news/ebay-inc-reports-second-quart…
dieses Quartal Nettogewinnmarge >19/22% GAAP/non-GAAP, FCF 28%
https://finance.yahoo.com/news/ebay-inc-reports-second-quart…
OceanaGold
HJ1 Nettogewinnspanne 19,1%(q2 ~23,38), EBITDA Spanne ~46,1%
www.asx.com.au/asxpdf/20160728/pdf/438wsdl6fnqhwh.pdf
HJ1 Nettogewinnspanne 19,1%(q2 ~23,38), EBITDA Spanne ~46,1%
www.asx.com.au/asxpdf/20160728/pdf/438wsdl6fnqhwh.pdf
Ein KANDIDAT,
interessant was Sie machen(eine Peer von QTMM),
ich habe vorgestern ein Brokerupdate gelesen.
Sie sind noch unprofitabel, und prognostizieren eine Vorsteuergewinnspanne von ~31,14%(EBITDA ~34,4),
aaaber im letzten Jahr Ihrer Forecastzahlenreihe/2. Jahr (pot)Profitabilität,
daher wäre (im Falle des Erreichens, Dieser)vermutlich noch nicht das Letzte Wort gesprochen
www.nanocotechnologies.com/about-us/glance
interessant was Sie machen(eine Peer von QTMM),
ich habe vorgestern ein Brokerupdate gelesen.
Sie sind noch unprofitabel, und prognostizieren eine Vorsteuergewinnspanne von ~31,14%(EBITDA ~34,4),
aaaber im letzten Jahr Ihrer Forecastzahlenreihe/2. Jahr (pot)Profitabilität,
daher wäre (im Falle des Erreichens, Dieser)vermutlich noch nicht das Letzte Wort gesprochen
www.nanocotechnologies.com/about-us/glance
q2 Nettogewinnspanne 28,3%
Silver Wheaton
www.kitco.com/news/2016-08-11/Silver-Wheaton-Reports-Higher-…
Silver Wheaton
www.kitco.com/news/2016-08-11/Silver-Wheaton-Reports-Higher-…
Antwort auf Beitrag Nr.: 53.041.180 von Popeye82 am 11.08.16 17:15:23
Peers,
habe ich schon lange, unter den „Großen“, auf der Liste,
aber bis heute noch nie gekauft
Q2 Nettogewinnspanne +26,5%
Franco-Nevada
http://s21.q4cdn.com/700333554/files/doc_news/2016/August/v3…
Peers,
habe ich schon lange, unter den „Großen“, auf der Liste,
aber bis heute noch nie gekauft
Q2 Nettogewinnspanne +26,5%
Franco-Nevada
http://s21.q4cdn.com/700333554/files/doc_news/2016/August/v3…
Antwort auf Beitrag Nr.: 53.042.662 von Popeye82 am 11.08.16 20:04:34
"+" stimmt zwar auch, es sollte allerdings ein "~" sein
"+" stimmt zwar auch, es sollte allerdings ein "~" sein
Adjusted HJ1 Gewinnspanne ~15,46%,
Hier dürften wahrs. erst die Folgequartale noch ein bisschen aussagekräftiger werden
B2Gold
http://b2gold.mwnewsroom.com/Files/d0/d0811c2f-7600-41e3-b63…
Hier dürften wahrs. erst die Folgequartale noch ein bisschen aussagekräftiger werden
B2Gold
http://b2gold.mwnewsroom.com/Files/d0/d0811c2f-7600-41e3-b63…
Für so Einen kleinen Laden finde ich besonders beachtlich,
es ist allerdings wohl eine (R&D)Steuererstattung mit reingeflossen.
Nettogewinnspanne im Berichtszeitraum ~21,32%
Global Health
www.asx.com.au/asxpdf/20160818/pdf/439f3f38q3nlhg.pdf
es ist allerdings wohl eine (R&D)Steuererstattung mit reingeflossen.
Nettogewinnspanne im Berichtszeitraum ~21,32%
Global Health
www.asx.com.au/asxpdf/20160818/pdf/439f3f38q3nlhg.pdf
GlaxoSmithKline
www.hybridan.com/HybridanSCW/public/techpiece/LifescienceRev…
www.hybridan.com/HybridanSCW/public/techpiece/LifescienceRev…
Antwort auf Beitrag Nr.: 53.129.097 von Popeye82 am 24.08.16 17:25:49
Indivior plc
www.hybridan.com/HybridanSCW/public/techpiece/LifescienceRev…
Indivior plc
www.hybridan.com/HybridanSCW/public/techpiece/LifescienceRev…
Antwort auf Beitrag Nr.: 53.129.121 von Popeye82 am 24.08.16 17:28:29
Shire Plc
www.hybridan.com/HybridanSCW/public/techpiece/LifescienceRev…
Shire Plc
www.hybridan.com/HybridanSCW/public/techpiece/LifescienceRev…
Antwort auf Beitrag Nr.: 53.135.946 von Popeye82 am 25.08.16 14:16:38
Bioventix
www.hybridan.com/HybridanSCW/public/techpiece/AIMing_for_inc…
Bioventix
www.hybridan.com/HybridanSCW/public/techpiece/AIMing_for_inc…
Antwort auf Beitrag Nr.: 53.136.054 von Popeye82 am 25.08.16 14:28:04
Central Asia Metals
www.hybridan.com/HybridanSCW/public/techpiece/AIMing_for_inc…
Central Asia Metals
www.hybridan.com/HybridanSCW/public/techpiece/AIMing_for_inc…
Antwort auf Beitrag Nr.: 53.136.105 von Popeye82 am 25.08.16 14:33:55
small cap
Jarvis Securities
www.hybridan.com/HybridanSCW/public/techpiece/AIMing_for_inc…
small cap
Jarvis Securities
www.hybridan.com/HybridanSCW/public/techpiece/AIMing_for_inc…
Antwort auf Beitrag Nr.: 53.136.138 von Popeye82 am 25.08.16 14:36:06
Nahl Group
www.hybridan.com/HybridanSCW/public/techpiece/AIMing_for_inc…
Nahl Group
www.hybridan.com/HybridanSCW/public/techpiece/AIMing_for_inc…
Das ist von Der Marge schon im ziemlich oben liegendem Bereich,
ich finde Ihr Tätigkeitsfeld interessant
Volljahresnettogewinnspanne ~30,6%
Pacific Energy
www.asx.com.au/asxpdf/20160825/pdf/439ml950hmlzdk.pdf
ich finde Ihr Tätigkeitsfeld interessant
Volljahresnettogewinnspanne ~30,6%
Pacific Energy
www.asx.com.au/asxpdf/20160825/pdf/439ml950hmlzdk.pdf
Antwort auf Beitrag Nr.: 53.137.776 von Popeye82 am 25.08.16 17:26:25
von Der Marge schon im ziemlich oben liegendem Bereich
_______________________________________________________
Geht noch höher.
q2 Nettogewinnspanne ~39,25%
http://ceapro.com/2016/08/24/ceapro-inc-reports-second-quart…
von Der Marge schon im ziemlich oben liegendem Bereich
_______________________________________________________
Geht noch höher.
q2 Nettogewinnspanne ~39,25%
http://ceapro.com/2016/08/24/ceapro-inc-reports-second-quart…
ein KANDIDAT.
kompliziertes Ding
Dimerix
http://dimerix.com/wp-content/uploads/2016-08-25-Dimerix-rep…
kompliziertes Ding
Dimerix
http://dimerix.com/wp-content/uploads/2016-08-25-Dimerix-rep…
ein pot. hochmargiges bis sehr hochmargiges (Gold)Projekt in Australien
Gold Road Resources
www.goldroad.com.au/reports/Canaccord-LikeChalkandCheese-23.…
Gold Road Resources
www.goldroad.com.au/reports/Canaccord-LikeChalkandCheese-23.…
Ein miniminismallcap,
q1 Nettogewinnspanne ~20,46%
China Education Resources
www.chinaeducationresources.com/s/Inthenews.asp?ReportID=761…
q1 Nettogewinnspanne ~20,46%
China Education Resources
www.chinaeducationresources.com/s/Inthenews.asp?ReportID=761…
Antwort auf Beitrag Nr.: 53.044.363 von Popeye82 am 12.08.16 00:42:42
https://gallery.mailchimp.com/3c4aa62f5be7d2078cdc62469/file…
https://gallery.mailchimp.com/3c4aa62f5be7d2078cdc62469/file…
So ein hässlicher OTC,
q2 Nettogewinnspanne ~41,0699979(!)%
Kiwa Bio-Tech Products
www.kiwabiotech.com/index.php/news/view?id=174
q2 Nettogewinnspanne ~41,0699979(!)%
Kiwa Bio-Tech Products
www.kiwabiotech.com/index.php/news/view?id=174
Das KANN mal ein MargenMonster werden.
Zu Observationen,
Wo?, Wie?, Weshalb?,
und Wer?, mit Wem?(und Waruuuuum???(das ist doch die Dorfmatratze!!!!!)),
und wie die Chancen darauf stehen,
oder auch nicht
Folgend:
www.resapphealth.com.au/wp-content/uploads/2016/11/RAP_Initi…
Zu Observationen,
Wo?, Wie?, Weshalb?,
und Wer?, mit Wem?(und Waruuuuum???(das ist doch die Dorfmatratze!!!!!)),
und wie die Chancen darauf stehen,
oder auch nicht
Folgend:
www.resapphealth.com.au/wp-content/uploads/2016/11/RAP_Initi…
Kandidat,
Blockchain,
interessanter Lesestoff:
Kyckr
www.kyckr.com/wp-content/uploads/2016/11/KYK_Initiating-Cove…
Blockchain,
interessanter Lesestoff:
Kyckr
www.kyckr.com/wp-content/uploads/2016/11/KYK_Initiating-Cove…
Antwort auf Beitrag Nr.: 53.271.135 von Popeye82 am 14.09.16 00:26:25
interessant zu lesen:
www.equities.com/news/kiwa-bio-kwbt-a-bio-tech-leader-in-the…
Zitat von Popeye82: So ein hässlicher OTC,
q2 Nettogewinnspanne ~41,0699979(!)%
Kiwa Bio-Tech Products
www.kiwabiotech.com/index.php/news/view?id=174
interessant zu lesen:
www.equities.com/news/kiwa-bio-kwbt-a-bio-tech-leader-in-the…
FY 9monats Ergebnis, Nettogewinnspanne 9monate/letztes Quartals: ~23,33/~27,4%:
http://silvercorpmetals.com/_resources/news/nr_20170202.pdf
http://silvercorpmetals.com/_resources/news/nr_20170202.pdf
Antwort auf Beitrag Nr.: 54.239.875 von Popeye82 am 04.02.17 17:56:14
www.silvercorpmetals.com/news_and_media/news/index.php?conte…
www.silvercorpmetals.com/news_and_media/news/index.php?conte…
Antwort auf Beitrag Nr.: 53.050.858 von Popeye82 am 12.08.16 18:41:02http://www.b2gold.com/news/index.php?content_id=574
Antwort auf Beitrag Nr.: 57.289.702 von Popeye82 am 15.03.18 16:32:51http://www.b2gold.com/news/index.php?content_id=582
Hast du dich eingekauft oder beobachtest du nur?
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
105 | ||
84 | ||
72 | ||
56 | ||
45 | ||
39 | ||
35 | ||
26 | ||
18 | ||
18 |
Wertpapier | Beiträge | |
---|---|---|
17 | ||
17 | ||
14 | ||
13 | ||
12 | ||
11 | ||
11 | ||
10 | ||
10 | ||
9 |